top of page
CLINICAL STUDIES
Kidney transplantation
Mercury.
A Phase 3 Prospective, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
â
Funded by Medeor Therapeutics, Inc
bottom of page